Survival outcomes and time toxicity of Sandwich versus Sequential chemoradiation in Stage III endometrial cancer: A real-world study stratified by molecular classification.

OBJECTIVE To evaluate the survival outcomes of Sandwich (Chemo-RT-Chemo) versus Sequential (Chemo-RT) therapy in Stage III endometrial cancer, focusing on the interplay between treatment intervals, time toxicity, and molecular classification. METHODS We analyzed 119 patients with Stage III EC (2015-2025) receiving either Sequential (n = 42) or Sandwich (n = 77) regimens. Endpoints included overall survival (OS), progression-free survival (PFS), relative dose intensity (RDI), and overall treatment time (OTT). Outcomes were stratified by p53 and MMR status. RESULTS Among 119 patients (42 Sequential, 77 Sandwich) with well-balanced characteristics, no significant differences were observed in OS (P = .73) or PFS (P = .93). However, subgroup analysis favored the Sandwich regimen in pMMR tumors (PFS benefit, P = .026) and p53-mutant tumors (improved time-to-recurrence, P = .034). Regarding time toxicity, the Sandwich cohort demonstrated significantly shorter median overall treatment time (198.0 vs. 223.0 days; P < .001) and earlier radiotherapy initiation (77.0 vs. 171.5 days; P < .001). Chemotherapy dose intensity remained comparable (P = .878). While low-grade diarrhea was more frequent in the Sandwich arm (43% vs. 21%; P = .027), grade≧3 adverse events were rare and similar between groups. CONCLUSIONS The Sandwich regimen offers a dual advantage: it reduces patient time toxicity and ensures earlier pelvic control without sacrificing chemotherapy intensity. This optimized temporal sequencing appears particularly beneficial for high-risk molecular subtypes (p53-mutant/pMMR) and supports the paradigm of molecular-directed adjuvant therapy.

• Publication year

  2026

• Venue

  Gynecologic Oncology

• Publication date

  2026-02-23

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ygyno.2026.02.007PMID 41734477
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial.

  2026cited by this paper
• Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258.

  2025cited by this paper
• Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial

  2025cited by this paper
• Synergistic effect of MDM2 inhibitors and radiotherapy in endometrial cancer

  2025cited by this paper
• Prognosis of polymerase epsilon (POLE) mutation in high-grade endometrioid endometrial cancer: Systematic review and meta-analysis

  2024cited by this paper
• Lunchbox trial: A randomized phase III trial of cisplatin and irradiation followed by carboplatin and paclitaxel versus sandwich therapy of carboplatin and paclitaxel followed by irradiation then carboplatin and paclitaxel for advanced endometrial carcinoma.

  2023cited by this paper
• Mutant p53 in cancer: from molecular mechanism to therapeutic modulation

  2022cited by this paper
• Endometrial cancer.

  2022cited by this paper
• A Multi-Institutional Analysis of Adjuvant Chemotherapy and Radiation Sequence in Women with Stage IIIC Endometrial Cancer.

  2021cited by this paper
• Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer.

  2019cited by this paper
• Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial

  2019cited by this paper
• A multi-institutional analysis of sequential versus ‘sandwich’ adjuvant chemotherapy and radiotherapy for stage IIIC endometrial carcinoma

  2018cited by this paper
• Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial

  2018cited by this paper
• AACR Project GENIE: Powering Precision Medicine through an International Consortium.

  2017cited by this paper
• Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1.

  2015cited by this paper
• Sequential versus "sandwich" sequencing of adjuvant chemoradiation for the treatment of stage III uterine endometrioid adenocarcinoma.

  2015cited by this paper
• Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.

  2015cited by this paper
• Quantifying the risk of recurrence and death in stage III (FIGO 2009) endometrial cancer.

  2013cited by this paper
• A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a "Sandwich" method for stage III, IV, and recurrent endometrial cancer.

  2011cited by this paper
• A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer.

  2009cited by this paper
• Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up.

  1995cited by this paper
• Dose-response effect of adjuvant chemotherapy in breast cancer.

  1981cited by this paper

• No citing papers are available for this paper.